Ligand Enters Into License Agreement with Emergent BioSolutions


SAN DIEGO–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Emergent BioSolutions Inc. (NYSE: EBS), a global specialty biopharmaceutical company that focuses on emerging health threats, as well as oncology, transplantation, infectious diseases and autoimmune disorders. Under the license, Emergent will use the OmniRat®, OmniMouse® and OmniFlic® technologies to discover fully human mono- and bispecific antibodies. Ligand will be eligible to receive annual access payments, fees on patent filings, potential milestone payments and royalties on future net sales of any antibodies discovered under the license.

Subscribe to get the latest news